Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026
Huanglian ointment alleviates itching in allergic contact dermatitis via inhibition of the neuroimmune axis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Yun, Shen Zhou-Yang, Sun Xin, Ma Wen-Ya, Wang Rui-Qi, Xie Xiao-Yao, Wang Chang-Ming, Chan-Zhu, Yan-Yang, Chen Fei-Yan, Jiang Yu-Cui, Tang Zong-Xiang
Аннотация
BACKGROUND: Allergic contact dermatitis (ACD) is a common and debilitating disease with a lifetime prevalence of 20%. Recently, the mast cell Mas-related G protein-coupled receptor B2 (MrgprB2) has been implicated in the pathogenesis of pruritus in ACD. Huanglian Ointment (HLO) demonstrates significant clinical efficacy in promoting skin healing, treating eczema, and alleviating skin inflammation and itching. However, the mechanism underlying the antipruritic effects of HLO has not yet been elucidated.
PURPOSE: This study aims to elucidate the potential mechanism underlying the therapeutic effect of HLO against ACD via the MrgprB2-mediated neuroimmune axis.
METHODS: In this study, scratching behavioral assays, transgenic mice (MrgprB2-/- mice), histopathological analysis, immunofluorescence, whole-cell patch-clamp technique, HPLC analysis, UHPLC-MS/MS, molecular docking and Bio-layer Interferometry (BLI) were employed to investigate the potential antipruritic mechanisms of HLO and berberine.
RESULTS: Here, we demonstrated that HLO ameliorated pruritus in the oxazolone-induced ACD model by inhibiting mast cell activation and the subsequent release of tryptase, thereby reducing the abnormal excitability of dorsal root ganglion (DRG) neurons. In addition, knockout of MrgprB2 receptor could significantly reduce oxazoline-induced pruritus, tryptase release, and the abnormal excitability of DRG neurons. Notably, the therapeutic effect of HLO was significantly weakened in MrgprB2-/- mice, indicating that the mechanism underlying the antipruritic effect of HLO is potentially related to the MrgprB2-mediated neuroimmune axis. Furthermore, component analysis of HLO combined with molecular docking screening suggested that berberine could serve as one of the potential key bioactive components. BLI assays implied a relatively preferable binding interaction between berberine and MrgprX2 protein. Further data also indicated that berberine might mitigate pruritus in ACD model, and such anti-pruritic activity is presumably correlated with the MrgprB2 receptor.
CONCLUSION: In conclusion, our findings indicated that HLO could effectively alleviate pruritus, and this effect may be linked to the MrgprB2-related neuroimmune axis. Berberine may potentially act as an active component involved in HLO's antipruritic pharmacological effects.
PURPOSE: This study aims to elucidate the potential mechanism underlying the therapeutic effect of HLO against ACD via the MrgprB2-mediated neuroimmune axis.
METHODS: In this study, scratching behavioral assays, transgenic mice (MrgprB2-/- mice), histopathological analysis, immunofluorescence, whole-cell patch-clamp technique, HPLC analysis, UHPLC-MS/MS, molecular docking and Bio-layer Interferometry (BLI) were employed to investigate the potential antipruritic mechanisms of HLO and berberine.
RESULTS: Here, we demonstrated that HLO ameliorated pruritus in the oxazolone-induced ACD model by inhibiting mast cell activation and the subsequent release of tryptase, thereby reducing the abnormal excitability of dorsal root ganglion (DRG) neurons. In addition, knockout of MrgprB2 receptor could significantly reduce oxazoline-induced pruritus, tryptase release, and the abnormal excitability of DRG neurons. Notably, the therapeutic effect of HLO was significantly weakened in MrgprB2-/- mice, indicating that the mechanism underlying the antipruritic effect of HLO is potentially related to the MrgprB2-mediated neuroimmune axis. Furthermore, component analysis of HLO combined with molecular docking screening suggested that berberine could serve as one of the potential key bioactive components. BLI assays implied a relatively preferable binding interaction between berberine and MrgprX2 protein. Further data also indicated that berberine might mitigate pruritus in ACD model, and such anti-pruritic activity is presumably correlated with the MrgprB2 receptor.
CONCLUSION: In conclusion, our findings indicated that HLO could effectively alleviate pruritus, and this effect may be linked to the MrgprB2-related neuroimmune axis. Berberine may potentially act as an active component involved in HLO's antipruritic pharmacological effects.